Literature DB >> 24604591

Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.

Sarah M Cheal1, Blesida Punzalan, Michael G Doran, Michael J Evans, Joseph R Osborne, Jason S Lewis, Pat Zanzonico, Steven M Larson.   

Abstract

PURPOSE: The PET tracer, (124)I-cG250, directed against carbonic anhydrase IX (CAIX) shows promise for presurgical diagnosis of clear-cell renal cell carcinoma (ccRCC) (Divgi et al. in Lancet Oncol 8:304-310, 2007; Divgi et al. in J Clin Oncol 31:187-194, 2013). The radiometal (89)Zr, however, may offer advantages as a surrogate PET nuclide over (124)I in terms of greater tumor uptake and retention (Rice et al. in Semin Nucl Med 41:265-282, 2011). We have developed a nonlinear immunokinetic model to facilitate a quantitative comparison of absolute uptake and antibody turnover between (124)I-cG250 and (89)Zr-cG250 using a human ccRCC xenograft tumor model in mice. We believe that this unique model better relates quantitative imaging data to the salient biological features of tumor antibody-antigen binding and turnover.
METHODS: We conducted experiments with (89)Zr-cG250 and (124)I-cG250 using a human ccRCC cell line (SK-RC-38) to characterize the binding affinity and internalization kinetics of the two tracers in vitro. Serial PET imaging was performed in mice bearing subcutaneous ccRCC tumors to simultaneously detect and quantify time-dependent tumor uptake in vivo. Using the known specific activities of the two tracers, the equilibrium rates of antibody internalization and turnover in the tumors were derived from the PET images using nonlinear compartmental modeling.
RESULTS: The two tracers demonstrated virtually identical tumor cell binding and internalization but showed markedly different retentions in vitro. Superior PET images were obtained using (89)Zr-cG250, owing to the more prolonged trapping of the radiolabel in the tumor and simultaneous washout from normal tissues. Estimates of cG250/CAIX complex turnover were 1.35 - 5.51 × 10(12) molecules per hour per gram of tumor (20 % of receptors internalized per hour), and the ratio of (124)I/(89)Zr atoms released per unit time by tumor was 17.5.
CONCLUSION: Pairwise evaluation of (89)Zr-cG250 and (124)I-cG250 provided the basis for a nonlinear immunokinetic model which yielded quantitative information about the binding and internalization of radioantibody bound to CAIX on tumor cells in vivo. (89)Zr-cG250 is likely to provide high-quality PET images and may be a useful tool to quantify CAIX/cG250 receptor turnover and cG250-accessible antigen density noninvasively in humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604591      PMCID: PMC4120276          DOI: 10.1007/s00259-013-2679-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores.

Authors:  O W Press; K DeSantes; S K Anderson; F Geissler
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

2.  Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney.

Authors:  E Oosterwijk; D J Ruiter; P J Hoedemaeker; E K Pauwels; U Jonas; J Zwartendijk; S O Warnaar
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

3.  Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.

Authors:  F Geissler; S K Anderson; P Venkatesan; O Press
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

4.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

5.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

Authors:  P M Smith-Jones; S Vallabahajosula; S J Goldsmith; V Navarro; C J Hunter; D Bastidas; N H Bander
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

6.  Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate.

Authors:  Geoffrey Y Berguig; Anthony J Convertine; Julie Shi; Maria Corinna Palanca-Wessels; Craig L Duvall; Suzie H Pun; Oliver W Press; Patrick S Stayton
Journal:  Mol Pharm       Date:  2012-11-05       Impact factor: 4.939

7.  Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

Authors:  Adrienne H Brouwers; Wilhelmina C A M Buijs; Egbert Oosterwijk; Otto C Boerman; Carola Mala; Pieter H M De Mulder; Frans H M Corstens; Peter F A Mulders; Wim J G Oyen
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

8.  PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.

Authors:  Adrienne Brouwers; Iris Verel; Julliëtte Van Eerd; Gerard Visser; Martijn Steffens; Egbert Oosterwijk; Frans Corstens; Wim Oyen; Guus Van Dongen; Otto Boerman
Journal:  Cancer Biother Radiopharm       Date:  2004-04       Impact factor: 3.099

9.  Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Authors:  Adrienne H Brouwers; Julliëtte E M van Eerd; Cathelijne Frielink; Egbert Oosterwijk; Wim J G Oyen; Frans H M Corstens; Otto C Boerman
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

10.  Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Authors:  Iris Verel; Gerard W M Visser; Ronald Boellaard; Otto C Boerman; Julliette van Eerd; Gordon B Snow; Adriaan A Lammertsma; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

View more
  21 in total

1.  Investigation of the complexation of natZr(iv) and 89Zr(iv) by hydroxypyridinones for the development of chelators for PET imaging applications.

Authors:  F Guérard; M Beyler; Y-S Lee; R Tripier; J-F Gestin; M W Brechbiel
Journal:  Dalton Trans       Date:  2017-04-05       Impact factor: 4.390

2.  ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo.

Authors:  Kirstin A Zettlitz; Richard Tavaré; Scott M Knowles; Kristopher K Steward; John M Timmerman; Anna M Wu
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

Review 3.  Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.

Authors:  Kenneth M Tichauer; Yu Wang; Brian W Pogue; Jonathan T C Liu
Journal:  Phys Med Biol       Date:  2015-07-02       Impact factor: 3.609

4.  Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.

Authors:  Jimson W D'Souza; Harvey Hensley; Mohan Doss; Charles Beigarten; Michael Torgov; Tove Olafsen; Jian Q Yu; Matthew K Robinson
Journal:  J Nucl Med       Date:  2016-08-18       Impact factor: 10.057

Review 5.  PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  PET Clin       Date:  2015-04-24

6.  PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Authors:  Pat Zanzonico; Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Peter Smith-Jones; Shutian Ruan; Chaitanya Divgi; Andrew M Scott; Nancy E Kemeny; Yuman Fong; Douglas Wong; David Scheinberg; Gerd Ritter; Achem Jungbluth; Lloyd J Old; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-21       Impact factor: 9.236

Review 7.  ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.

Authors:  Reyhaneh Manafi-Farid; Bahar Ataeinia; Shaghayegh Ranjbar; Zahra Jamshidi Araghi; Mohammad Mobin Moradi; Christian Pirich; Mohsen Beheshti
Journal:  Front Med (Lausanne)       Date:  2022-06-28

8.  Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.

Authors:  Peng-Cheng Lv; Karson S Putt; Philip S Low
Journal:  Bioconjug Chem       Date:  2016-07-07       Impact factor: 4.774

9.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

Review 10.  Tumor immunotargeting using innovative radionuclides.

Authors:  Françoise Kraeber-Bodéré; Caroline Rousseau; Caroline Bodet-Milin; Cédric Mathieu; François Guérard; Eric Frampas; Thomas Carlier; Nicolas Chouin; Ferid Haddad; Jean-François Chatal; Alain Faivre-Chauvet; Michel Chérel; Jacques Barbet
Journal:  Int J Mol Sci       Date:  2015-02-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.